DoNews7月25日消息,7月25日,南京维立志博生物科技股份有限公司(下称“维立志博”)正式登陆港交所。发行价为35港元/股,一度上涨127% 。截至目前,市值达到136亿港元。招股书显示,维立志博是一家处于临床阶段的生物科技公司,产品研究主要集中在治疗肿瘤、自身免疫性疾病及其他重大疾病。目前,公司在研管线有12项,其中有6款产品进入到临床阶段。具体来看,公司核心产品LBL-024已于2024...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.